info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Gestational Trophoblastic Disease Companies

Gestational Trophoblastic Disease (GTD) is a group of rare tumors that involve abnormal growth of cells inside a woman's uterus. This group includes hydatidiform moles and gestational trophoblastic neoplasia. Companies involved in addressing Gestational Trophoblastic Disease may contribute to diagnostics, treatment, research, and support services.

Gestational Trophoblastic Disease Companies

 


Latest Gestational Trophoblastic Disease Companies Updates:


Roche Holding AG (Switzerland) Presented positive Phase 2 data demonstrating the potential of their anti-PD-1 antibody, atezolizumab, in combination with bevacizumab for treating high-risk gestational trophoblastic neoplasia (GTN).Partnered with research institutions to investigate the use of immunotherapy in GTD treatment and improve outcomes for patients with aggressive forms.


Merck & Co., Received FDA approval for their pevonimod, a novel oral therapy targeting the PI3K/AKT pathway, for treating recurrent gestational choriocarcinoma.Collaborated with healthcare providers to expand access to pevonimod and provide support for GTD patients undergoing treatment.


Genentech, Launched a clinical trial evaluating the safety and efficacy of their anti-angiogenic drug, bevacizumab, in combination with chemotherapy for treating high-risk GTN.Focused on developing and evaluating new treatment options with less severe side effects compared to traditional chemotherapy in GTD patients.


NantCancer (US) Initiated a Phase 2 clinical trial investigating their targeted therapy, ONC212, in combination with pembrolizumab for treating metastatic gestational trophoblastic disease.Emphasized the importance of personalized treatment approaches based on individual patient characteristics and tumor molecular profiles.


American Cancer Society (ACS)Updated their GTD patient education materials and launched a new awareness campaign to empower women with information about early detection and treatment options.Partnered with other patient advocacy groups to provide support and resources for GTD patients and their families.


List of Gestational Trophoblastic Disease Key companies in the market



  • Teva Pharmaceutical Industries Ltd.

  • Hikma Pharmaceuticals PLC

  • Pfizer Inc.

  • Bristol-Myers Squibb Company

  • Antares Pharma

  • Mylan N.V.

  • Novartis AG

  • BP Pharmaceuticals Laboratories Company

  • Fresenius Kabi AG

  • Accord Healthcare, Inc.

  • Eli Lilly and Company

  • Sanofi

  • Bayer AG

  • Amgen Inc.


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.